FDA Brief

Warning letters Drugs

FDA warning letter to

Matthew Stern, CEO MyStart Health LLC.

LowIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.

What happened

FDA reviewed the website https://www.mystarthealth.com in August 2025. The site offers compounded semaglutide (semaglutide made by a compounding pharmacy, not an FDA-approved manufacturer) and uses claims including 'Generic Ozempic' and 'Save with generics that offer the same active ingredients and results.' FDA says these claims are false or misleading because compounded drugs are not FDA-approved and the claims imply the products are the same as an FDA-approved product.

What FDA found

  1. The website called its compounded semaglutide 'Generic Ozempic,' falsely implying it is the same as FDA-approved Ozempic.

    FDCA section 502(a) [21 U.S.C. § 352(a)]
  2. The website said its generics offer 'the same active ingredients and results,' a misleading claim because compounded drugs are not FDA-approved.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  3. The company introduced or delivered misbranded drugs into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. Receiving or delivering misbranded drugs in interstate commerce is also prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells MyStart Health to take immediate action, including stopping the misleading language, and to send a written response within 15 working days describing steps taken, how it will prevent recurrence, and related documents. If it cannot fully address the matter in that time, it must explain the delay and when it will.

Who should pay attention

  • telehealth companies selling compounded semaglutide
  • compounding pharmacies and online pharmacies that compare their drugs to brand-name products
  • marketing and compliance teams for prescription drug websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low